Rituximab-based immunosuppression for autoimmune haemolytic anaemia in infants

Area of Science:

• Pediatric Hematology
• Immunology
• Clinical Therapeutics

Background:

• Severe autoimmune haemolytic anaemia (AIHA) in infants presents a significant clinical challenge.
• First-line treatment with high-dose steroids (prednisolone 4-8 mg/kg/d) is not always effective.

Observation:

• A case series of four infants with severe AIHA who failed initial steroid therapy was analyzed.
• Rituximab treatment was initiated between 11-90 days from symptom onset due to persistent haemolysis.
• Three of the four infants also received cyclosporine A concurrently.

Findings:

• Three out of four infants achieved a complete response, characterized by normalized hemoglobin, reticulocyte counts, and resolution of haemolysis markers.
• Complete response was observed between 7-21 months post-diagnosis.
• Long-term follow-up revealed two infants remained disease-free with normal immunological profiles.

Implications:

• Rituximab and cyclosporine A represent a promising therapeutic option for severe AIHA in infants refractory to steroid treatment.
• This combination therapy may improve long-term outcomes and reduce disease burden in pediatric AIHA.
• Further research is warranted to explore the long-term immunological effects and optimal use of these agents in pediatric AIHA.